Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Case Report

Published on 15 Jan 2025

Case report: Tocilizumab for hypersensitivity reaction after oxaliplatin in a patient with NK/T-cell lymphoma

in Pharmacology of Anti-Cancer Drugs

Juanyan Liao
Ming Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1471038

822 views
1 citation

Original Research

Published on 15 Jan 2025

Parishin B blocking TRIB3-AKT1 interaction inhibits breast cancer lung metastasis

in Pharmacology of Anti-Cancer Drugs

Xiongtao Cheng
Jianguo Sun
Shouhong Chen
Nan Wang
Weijing Tang
Zijian Xia
Yuhong Shu
Shouhong Gao
Zhipeng Wang
Xinxia Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1517708

988 views

Original Research

Published on 15 Jan 2025

Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR/PI3K/AKT/GPX4 signalling axis

in Pharmacology of Anti-Cancer Drugs

Lei Xiang
Qingzhou Li
Zhiwei Guan
Guilin Wang
Xiankuo Yu
Xianwen Zhang
Guochen Zhang
Jushan Hu
Xue Yang
Mingrui Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1527286

1,244 views

Original Research

Published on 15 Jan 2025

Intratumor microbiome-derived butyrate promotes chemo-resistance in colorectal cancer

in Pharmacology of Anti-Cancer Drugs

Linsheng Xu
Bingde Hu
Jingli He
Xin Fu
Na Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1510851

1,398 views
1 citation

Review

Published on 15 Jan 2025

The mechanism underlying metastasis in triple-negative breast cancer: focusing on the interplay between ferroptosis, epithelial-mesenchymal transition, and non-coding RNAs

in Pharmacology of Anti-Cancer Drugs

Ziyi Chen
Yi Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1437022

1,495 views

Original Research

Published on 14 Jan 2025

DNA methylation inhibitors adverse reaction characteristic analysis: an analysis based on the European spontaneous adverse event reporting system

in Pharmacology of Anti-Cancer Drugs

Xia Zhang
Yuyu Liu
Qingwang Hou
Yongxin Guo
Youfu He

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1527903

723 views

Review

Published on 14 Jan 2025

Hydroxysafflor yellow A: a natural pigment with potential anticancer therapeutic effect

in Pharmacology of Anti-Cancer Drugs

Yuhan Wang
Junsha An
Jianbo Zhou
Liming Chang
Quan Zhang
Fu Peng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1495393

1,110 views
2 citations

Original Research

Published on 13 Jan 2025

Integration of histone modification-based risk signature with drug sensitivity analysis reveals novel therapeutic strategies for lower-grade glioma

in Pharmacology of Anti-Cancer Drugs

Jingyuan Wang
Shuai Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1523779

1,198 views

Original Research

Published on 13 Jan 2025

CSNK1E is involved in TGF-β1 induced epithelial mesenchymal transformationas and related to melanoma immune heterogeneity

in Pharmacology of Anti-Cancer Drugs

Wangbing Hong
Xin Wang
Xinyu Huang
Pengfei Chen
Yifan Liu
Ziying Zheng
Xin You
Yinghua Chen
Zengxin Xie
Gongnan Zhan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1501849

802 views

Review

Published on 10 Jan 2025

Targeting the initiator to activate both ferroptosis and cuproptosis for breast cancer treatment: progress and possibility for clinical application

in Pharmacology of Anti-Cancer Drugs

Murshid Imam
Jiale Ji
Zhijie Zhang
Shunchao Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1493188

1,779 views

Original Research

Published on 09 Jan 2025

Computer-assisted discovery of natural inhibitors for platelet-derived growth factor alpha as novel therapeutics for thyroid cancer

in Pharmacology of Anti-Cancer Drugs

Hira Khalid
Farah Sattar
Iqra Ahmad
Valdir Ferreira de Paula Junior
Umar Nishan
Riaz Ullah
Hanna Dib
Khaled W. Omari
Mohibullah Shah

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1512864

1,625 views

Brief Research Report

Published on 09 Jan 2025

Urolithin A increases the natural killer activity of PBMCs in patients with prostate cancer

in Pharmacology of Anti-Cancer Drugs

Vladimir Rogovskii
Vladimir V. Murugin
Nikolay Vorobyev
Sergey Popov
Nikolay Sturov
Alexey Krasheninnikov
Alexander Morozov
Marina Prokhorova

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1503317

1,403 views
3 citations

Original Research

Published on 09 Jan 2025

Gut microbiota derived metabolite trimethylamine N-oxide influences prostate cancer progression via the p38/HMOX1 pathway

in Pharmacology of Anti-Cancer Drugs

Yuhua Zhou
Jing Lv
Shengkai Jin
Chaowei Fu
Bo Liu
Yang Shen
Menglu Li
Yuwei Zhang
Ninghan Feng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1526051

1,358 views
1 citation

Review

Published on 09 Jan 2025

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)

in Pharmacology of Anti-Cancer Drugs

Qingjian He
Junling Lin
Chanjuan Mo
Guodong Li
Jianzhong Lu
Qiyin Sun
Lijun Cao
Haojian Gan
Quan Sun
Jiafang Yao

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1463520

1,156 views

Systematic Review

Published on 07 Jan 2025

Global research landscape and emerging trends of non-coding RNAs in prostate cancer: a bibliometric analysis

in Pharmacology of Anti-Cancer Drugs

Yu-Liang Zhou
Wen-Liang Yao
Sheng-Hui Chen
Peng Wang
Jing-Wen Fu
Jia-Qin Zhao
Jia-Yi Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1483186

1,414 views

Review

Published on 06 Jan 2025

Bergenin, a bioactive flavonoid: advancements in the prospects of anticancer mechanism, pharmacokinetics and nanoformulations

in Pharmacology of Anti-Cancer Drugs

Pratibha Pandey
Sorabh Lakhanpal
Danish Mahmood
Han Na Kang
Byunggyu Kim
Sojin Kang
Jinwon Choi
Seungjoon Moon
Shivam Pandey
Suhas Ballal

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1481587

1,327 views